RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

European Cancer Organisation - Time to Act

European Cancer Organisation: Time To Act

Special Issue: Women’s cancer care in fragile, conflict-impacted ecosystems

Women's cancers in the Democratic Republic of Congo

Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases

Psycho-oncology service provisions for hospitalised cancer patients before and during the COVID19 pandemic

OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021

UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients with EGFRm NSCLC with uncommon mutations

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer

Efficacy and early discontinuation predictors in NSCLC patients receiving nivolumab

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours